Contrary to expectations that anti-PD-L1/PD-1 therapies could be effective in ovarian cancers, clinical trials showed that their performance remains restricted—first of all, because the expression of PDL-1 is modest in ovarian carcinomas [96]. This evidence concerns the gene CD274 and ovarian carcinoma.